We are pleased to announce that an article analysing glycaemic control in patients enrolled in the DISCOVER study titled ‘Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme’ has now been published in Diabetes, Obesity and Metabolism.¹

The article describes the glycated haemoglobin (HbA_1c) levels in patients enrolled in DISCOVER from 37 countries across six continents at the initiation of second-line therapy (baseline), and the clinical and socioeconomic factors that were found to be associated with poor glycaemic control (defined as HbA_1c levels > 8.0%).

Overall, baseline HbA_1c level data were available for 80.9% of the patients enrolled in the study, with substantial regional variation in the proportion of patients with recorded baseline HbA_1c levels (across region range [ARR]: 57.5–98.2%). The overall mean HbA_1c level among these patients was 8.3% (ARR: 7.9–8.7%; Figure 1). More than 50.0% of the patients had an HbA_1c level ≥ 8.0%, and more than 25.0% of patients had an HbA_1c level ≥ 9.0%. Factors associated with poor baseline glycaemic control included living in a lower-middle-income country (versus living in a high-income country), a longer duration of type 2 diabetes and a lower education level.

The full article is available to read and download here!